Vicore Pharma to Participate in Upcoming Healthcare Conferences

Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences.

Rhea-AI Summary

Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences. At the Wells Fargo Healthcare Conference at Encore Boston Harbor in Boston, the company will hold 1×1 meetings on September 8 with CEO Ahmed Mousa. At the Cantor Global Healthcare Conference at the Waldorf Astoria New York, Mousa will join a fireside chat and 1×1 meetings on September 11 from 9:45–10:15 AM ET, which will be available via webcast.

Argus Sep 1 session

+0.28% close to close Open Argus

Details

News Market Reaction – VCRE

On Sep 1, the day this news came out, VCRE closed 0.28% above the previous close.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Participation date: September 8, 2026 Meeting format: 1×1 meetings Fireside chat date: September 11, 2026 +3 more

Participation date

September 8, 2026

Wells Fargo Healthcare Conference

Meeting format

1×1 meetings

Wells Fargo Healthcare Conference

Fireside chat date

September 11, 2026

Cantor Global Healthcare Conference

Fireside chat time

9:45-10:15 AM ET

Cantor Global Healthcare Conference

Trial duration

52-week

ASPIRE trial in idiopathic pulmonary fibrosis

Trial phase

Phase 2b

ASPIRE trial in idiopathic pulmonary fibrosis

Historical Context

3 past events · Latest: Aug 26

3 events

1. Aug 26

   Healthcare conference

   24h Move

   -1.5%

   Conference participation announcement; shares declined 1.48% over the following 24 hours.

2. Aug 24

   Respiratory congress

   24h Move

   -8.0%

   Conference presentation announcement; shares declined 8% over the following 24 hours.

3. Jul 07

   Investor forum

   24h Move

   -7.5%

   Investor forum participation announcement; shares declined 7.54% over the following 24 hours.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

idiopathic pulmonary fibrosis, orphan drug, fast track designation

3 terms

idiopathic pulmonary fibrosis medical

"disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

orphan drug regulatory

"has received Orphan Drug and Fast Track designation"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track designation regulatory

"has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences:

• Wells Fargo Healthcare Conference
  Location: Encore Boston Harbor, Boston, Mass.
  Format: 1×1 meetings
  Participation Date: Tuesday, September 8, 2026
  Participant: Ahmed Mousa, Chief Executive Officer

• Cantor Global Healthcare Conference
  Location: Waldorf Astoria New York, New York, N.Y.
  Format: Fireside chat and 1×1 meetings
  Fireside Chat Date and Time: Friday, September 11, 2026, 9:45-10:15 AM ET
  Webcast: Link
  Participant: Ahmed Mousa, Chief Executive Officer

For more information, please contact:

Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Participate in Upcoming Healthcare Conferences

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Vicore Pharma (VCRE) attend the Wells Fargo Healthcare Conference in 2026?

Vicore Pharma will participate in the Wells Fargo Healthcare Conference on Tuesday, September 8, 2026. According to the company, the event will take place at Encore Boston Harbor in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.

What is Vicore Pharma presenting at the Cantor Global Healthcare Conference 2026 (NASDAQ:VCRE)?

Vicore Pharma will join a fireside chat and 1×1 meetings at the Cantor Global Healthcare Conference. According to the company, the fireside chat is scheduled for Friday, September 11, 2026, from 9:45–10:15 AM ET at the Waldorf Astoria New York.

How can investors access Vicore Pharma’s Cantor Global Healthcare Conference 2026 webcast?

Vicore Pharma states that the Cantor fireside chat on September 11, 2026, from 9:45–10:15 AM ET will be available via webcast link. Investors can use the provided webcast link to listen to CEO Ahmed Mousa’s discussion.

Who will represent Vicore Pharma (VCRE) at the September 2026 healthcare conferences?

Vicore Pharma will be represented by Chief Executive Officer Ahmed Mousa at both the Wells Fargo and Cantor healthcare conferences. According to the company, he will participate in 1×1 meetings and a fireside chat with investors and stakeholders.

What is Vicore Pharma’s lead program mentioned in the September 2026 conference announcement?

Vicore Pharma’s lead program is buloxibutid, an oral angiotensin II type 2 receptor agonist. According to the company, it has Orphan Drug and Fast Track designations from the U.S. FDA and is being studied in the global 52-week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis.

On which stock exchanges is Vicore Pharma listed and under what symbols?

Vicore Pharma is listed on Nasdaq Stockholm as VICO and on Nasdaq US as VCRE. According to the company, it is a clinical-stage biopharmaceutical business focused on angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.